Friday, April 14, 2006

Treweren Spring News 2006

Well if anyone happens to read this, there is a news release on treweren's site
http://www.treweren.com/news1a.html



----

April 2006

Move those side-chains
Most developers of Virtual Screening software have succumbed to the temptation to ignore protein side-chain flexibility. Inevitably this means that hits are missed unless the contributions from VdW repulsions are reduced or hydrogens ignored. Unfortunately, one would expect these approximations to increase the numbers of false positive hits.

The increased computational power from Linux clusters and distributed computing has been used in recent years to increase the quantity of molecules screened. Little progress has been made in removing crude approximations or improving scoring functions. Docking algorithms which refine side-chain positions implicitly require a minimisation algorithm.

In our recent experience, Simplex is a poor choice of minimisation algorithm when refining side-chains. The reasons for this are two fold:

The Simplex algorithm performs badly when rotating many side-chain bonds
Each iteration requires the time-consuming intra-protein non-bonded energy to be recomputed.
THINK 1.32 includes a steepest descents minimiser to refine the ligand position, orientation, torsions and side-chain torsions. The following table shows some improved results over THINK 1.31 with NCI cancer cell line activity data:

Protein True positives False positives
1o4p-q1 13/14 38/68
1nvs-q1 10/13 32/61


These preliminary results used our revised scoring function with an additional penalty term for gaps between the ligand and the protein. In this example, extended protein atom radii were used in preference to explicit hydrogens which would be better but slower!

Find-a-Drug update
After nearly 300 queries searched, each with up to 0.5 billion drug-like molecules, and over 10,000 CPU years we have stopped generating data. We continue to pursue existing and new collaborations.


Screening without proteins
For a set of active molecules, the pharmacophores which occur most frequently in a pharmacophore profile can be used as search queries to generate the 3?D coordinates for conformers fitted to that pharmacophore. If each molecule has 2 conformers which exhibit the pharmacophore then for 8 active molecules there are 256 permutations of conformers, each of which has a corresponding union volume map. In general, it is reasonable to assume that for each pharmacophore the most credible union volume map is the one with the smallest volume corresponding to different molecules occupying the same space.



The union volume map can be used as a constraint in a pharmacophore search of a database or library. The use of such constraints eliminates a significant number of false positives during a search. Such maps which represent the volume used by active molecules are known as active volume constraint maps or ligand maps.

Towards a better scoring function
THINK uses an enhanced ChemScore function with

An intermolecular VdW term
A lipophilic-hydrophilic solvation term that penalises bad contacts
A charge dipole model to supersede the empirical hydrogen bond term
An improved ligand torsional entropy term.
In our experiments protein side-chain torsional entropy offered little improvement

Wednesday, December 28, 2005

The End

Well due to popular demand the automatic uninstallation was left a little longer to finish off the last query. Since that has finished, Uninstall will be automatically started the next time the client connects to Find-a-Drug as of the time of writing


Look out in the new year for a release of new certificates found to exhibit anti-??? activity.

Friday, December 16, 2005

Sousaphone + Supermarket = Delays

The auto-uninstalling of Find-a-Drug clients will be delayed due to a Sousaphone and a Supermarket


So the widspread uninstallation of the clients will be delayed until Monday 19th 2005(UK)

Tuesday, December 13, 2005

Alzheimer/Parkinson/Stroke - 1PMQ-Q1 - c-Jun N-terminal kinases (JNKs)

Proteome
1PMQ-Q1

c-Jun N-terminal kinases (JNKs)

c-Jun N-terminal kinases (JNKs) is a mitogen-activated protein kinase (MAPK) and JNK-3 is primarily found in certain nerve cells where is it plays a role in cell death. It has been identified as an attracive therapeutic target in Neurological disorders - especially Alzheimer's disease and Parkinson's disease. It has also been suggested that inhibitors to JNK-3 might be beneficial to stroke victims. This query is based on a different crystal structure to 1PMN-Q1.

Test jobs for this query gave average numbers of hits with many jobs completing in less time than typical jobs.? Description

L Resnick & M Fennell DDT (2004) 9.21 p932-939

Friday, December 09, 2005

Virus/Cancer - 1I3Z-Q1 - EWS/FLT1 Activated Transcript 2 (EAT-2)

Proteome
1I3Z-Q1

EWS/FLT1 Activated Transcript 2 ( EAT-2 )

The immune system produces Natural Killer (NK) cells in response to most virus infections and cancer tumours. EWS/FLT1 Activated Transcript 2 (EAT-2) suppresses the killer function and it has been suggested that a small molecule which inhibited EAT-2 might have therapeutic potential.

The job times for test queries varied often taking longer average jobs and giving more hits.

R Roncagalli et al Immunology (2005) 6 p 1002-1010

Cancer - 1I4O-Q1 - X-linked Inhibitor of Apoptosis Protein (XIAP)

Cancer
1I4O-Q1

X-linked Inhibitor of Apoptosis Protein (XIAP)

Inhibitor of Apoptosis proteins are often present in exceptionally high quantities in cancer tissues. It is believed that molecules which bind to X-linked Inhibitor of Apoptosis Protein (XIAP) induce cell death by freeing caspases.

The job times for test queries varied with most giving typical numbers of hits.

K Thorsten et al J Med Chem (2004) 47.18 p4417-26

Sunday, December 04, 2005

Cancer - 1M2G-Q1 - Silent information regulator 2 (Sir2)

Cancer
1M2G-Q1

Silent information regulator 2 ( Sir2 )

Silent information regulator 2 (Sir2) can deactivate p53 (a tumour suppressor protein) which is undesirable in tumours. Sir2 inhibitors have potential as novel anti-cancer drugs.

The times for test jobs were longer than average giving more hits.

J Posakony et al J Med Chem (2004) 47.10 p 2635-44

Thursday, December 01, 2005

Testing Auto-Uninstall Procedure

The beta testing of the Auto-uninstalation procedure has started today

It is anticipated that the software will automatically uninstall when the project closes on 16 December. In practice, this means that when a PC attempts to download jobs after the 16 December a new version of loader will be downloaded which will run automatically an uninstall the software.

To test this

1. Take a backup of the Find-a-Drug software folder including its cache subfolder. It may be a good idea to stop think before doing so and restart the software afterwards (ie run loader).

2. Download http://www.find-a-drug.net/uninstal/loader.exe for Windows or http://www.find-a-drug.net/uninstal/loader for Linux. Under Linux you will need to use chmod to make loader executable (chmod u+x loader). You must move loader to the folder containing the software!

3. Manually run loader.exe (windows) or loader (Linux)





This should:

1. Stop the software.

2. Remove think.lgo from startup folders and any service definitions created by 1.30 beta.

3. Remove Find-a-Drug Control Panel desktop icon and Find-a-Drug items under Start > Programs

4. Delete most of the contents of the software folder and cache subfolder (loader.exe and salflibc.dll are deliberately left behind under Windows just incase a non-standard startup procedure is being used). jobs.htm is also left behind. Depending on the version of THINK you originally installed and which (if any) test versions you ran there may be a few other files left.





We are aware that

1. Any non-standard startup procedure which references think.exe or fadsetup.exe will fail as these files have been removed.

2. 1.25 Linux users will probably see error message 26 relating to writing to computer.tlg. This can be ignored.

3. Registry entries are left behind - just incase they are useful in the future.


You should be able to restore the backup and continue processing the remaining queries after you have completed the test.

Diabetes/Obesity - 2SHP-Q2 - Tyrosine phosphatase SHP-2

Proteome
2SHP-Q2

Tyrosine phosphatase SHP-2

The molecular signalling associated with Diabetes and Obesity is complicated and not fully understand. Tyrosine phosphatase SHP-2 plays a role in this and it has been suggested that it may be an appropriate drug target.

Most test jobs took longer than average jobs and gave more hits.

P Hof et al, Cell (1998) 92 p 441-450

Cancer - 1JD4-Q1- Transcription Factor 4 (TCF4)

Cancer
1JD4-Q1

Transcription Factor 4 ( TCF4 )

Transcription Factor 4 (TCF4) is a known to interact with beta-catenin in several different ways. It is a recognised anti-cancer target although side-effects and selectivity are likely to be problematic.

The job times for test queries where typical often giving more hits.


J W Wu et al Mol Cell (2001) 8 p95-104

Monday, November 28, 2005

Tuberculosis - 1RRI-Q1 - 7,8-Dihydroneopterin Aldolase

Respiratory Diseases
1RRI-Q1

7,8-Dihydroneopterin Aldolase

7,8-Dihydroneopterin Aldolase ( DHNA ) has no human equivalent but is an essential enzyme in bacteria including Mycobacterium Tuberculosis, playing a critical role in folate synthesis. This is a novel antibacterial target which is interesting because bacteria in contrast to humans (and other mammals) cannot absorb folate from their environment. Without folate bacteria cannot grow! This query is based on a different crystal structure to 1nbu-q1.

This query gives above average number of hits and longer than typical job times.


W J Sanders et al J Med Chem (2004) 47.7 p1709-18

Cancer - 1BQO-Q1 - Stromelysin

Cancer
1BQO-Q1

Stromelysin

Stromelysin belongs to the class of Matrix MetallogProteinases (MMPs). It is a recognised anti-cancer target which is associated with tumour blood supply although finding clinically effective molecules has proven difficult. This query is based on a different protein crystal structure to 1b8y-q1 and 1biw-q1.

The times for test jobs were variable often giving more hits than average.

R C Rizzo et al J Med Chem (2004) 47.12 p3065-74

Saturday, November 26, 2005

Arthritis - 1FXF-Q1 - Phospholipase A2 (PLA2)

Proteome
1FXF-Q1

Phospholipase A2 (PLA2)

Phospholipase A2 (PLA2) cleaves ester bond in glycerophospholipids releasing free fatty acids and lysophospholipids. Excessive levels of human nonpancreatic PLA2 has been associated with a number of disease states including arthritis, septic shock and atherosclerosis. Inhibition of PLA2 may have therapeutic potential in the treatment of arthritis. This query is based on a different crystal structure than 1fx9-q1.

For test jobs, times and numbers of hits for this query where typical.


J S Sawyer et al J Med Chem (2005) 48.3 p893-6

Thursday, November 24, 2005

HIV - 1BDQ-Q1 - HIV Protease

HIV
1BDQ-Q1

HIV Protease

HIV protease is a recognised drug target. However, mutations of this protein render many of the inhibitors ineffective against mutant strains.

We expect this query to give above normal numbers of hits and below average job times on a typical PC.

A B Smith III, J Med Chem (2003) 46.10 p1831-44

Tuesday, November 22, 2005

Useful Chemisty

Useful Chemistry is using some of our result information for HIV & Malaria.

That's about all I know so go visit and have a read

Useful Chemisty Website

Cancer - 1O4P-Q1 - C-SRC Tyrosine Kinase

Cancer
1O4P-Q1

C-SRC Tyrosine Kinase

Tyrosine kinases occur widely in human tissues. Achieving selectivity is important to avoid side-effects especially if a drug is to be taken for a long period of time. C-SRC tyrosine kinase is a recognised anti-cancer drug target. This query is based on a different crystal structure to 1lcj-q1.

The job times for test queries varied sometimes taking longer average jobs and giving more hits.

L A Witucki et al Chem Biol (2002) 9.1 p25-33

Methodology - 1E7U-Q4 - Better Hits Included or Not / Cancer

Methodology
1E7U-Q4

Phosphatidylinositol 3 Kinase

Phosphatidylinositol 3 Kinase (PI3K) regulation of the Akt/PKB pathway is essential for cell survival. Inhibition of PI3K leads to apoptosis (cell death) as a consequence Akt/PKB not phosphorylating proteins including Bad, transcription factors, caspase-9 amd ASK-1. There is reason for thinking that cancer cells would be selectively killed by a PI3K inhibitor.

This query is part of a series which explores the use of less stringent queries that give more hits. We hope to gain an insight into whether better hits are generally included. Test jobs for this query took longer and gave more hits than typical jobs.

E H Walker et al (2000) Mol Cell Biol 6 p909

Wednesday, November 16, 2005

Cancer - 1EAX-Q1 - Matriptase

Cancer
1EAX-Q1

Matriptase

Matriptase belongs to the serine protease family of proteins. It has recently been identified as a cancer target. This query is based on a different crystal structure to 1eaw-q1.

The job times and number of hits for test queries varied.


R Friedrich and W Bode J Biol Chem (2001) 277 p2160

Monday, November 14, 2005

AntiBacterial - 1KZM - Gyrase B

Proteome
1KZM-Q1

Gyrase B

Gyrase is a recognised antibacterial target. However, existing inhibitors have not had therpeutic potential because of serious side-effects and mutant resistance. It may be possible to find alternative inhibitors which do not have these limitations. This query is based on a different crystal structure to 1a6j-q1.

Job times for this query varied with some jobs taking less time and giving fewer hits than average jobs.

A Tanitame et al J Med Chem (2004) 47.14 p3693-6

Saturday, November 12, 2005

Cancer - 1EAW-Q1 - Matriptase

Cancer
1EAW-Q1

Matriptase

Matriptase belongs to the serine protease family of proteins. It has recently been identified as a cancer target.

The job times for test queries took longer than average giving more hits.


R Friedrich and W Bode J Biol Chem (2001) 277 p2160




Snipet from the link
http://www.nih.gov/news/pr/aug2005/nidcr-15.htm
Scientists Find Cell Surface Enzyme Matriptase Causes Cancer
Scientists at the National Institute of Dental and Craniofacial Research (NIDCR) and colleagues report in animal studies that a single, scissor-like enzyme called matriptase, when left to its own devices, can cause cancer.

This finding, published in the current issue of the journal Genes and Development, marks the first report of a protein-cleaving enzyme, or protease, on the cell surface that can efficiently trigger the formation of tumor cells. The authors also note that matriptase is the first known cell-surface protease that can act as an oncogene, an umbrella term for mutated genes and their proteins that prompt cells to divide too rapidly, a hallmark of tumor cells.

“What makes matriptase potentially such a good molecular target to treat cancer is its accessibility,” said NIDCR scientist Dr. Thomas Bugge, the senior author on the paper. “We don’t have to trick the tumor cell to internalize a drug, then hope it reaches its destination in an appropriate concentration and duration. In this case, the bull’s eye is right on the cell surface.”


..... follow the link for more

Malaria - 1LS5-Q2 - Range extended

Plasmepsin IV, 1LS5-Q2 a Malaria target has been exteneded, initialy starting with jobs in the range 1550 to 19154.

Plasmodium falciparum (the parasite which causes Malaria) invades erythrocyte cells and consumes the host hemoglobin. Plasmepsin plays a key role digesting the protein and has been recognised as a novel target for anti-malaria drugs. Inhibition of hemoglobin degradation lead to toxic concentrations and parasite death in culture.